Publications

 


  • 528. Four-hundredfold overestimation of biopsy mortality.

    Carlsson S, Vickers A, Hugosson J, 2013

    Journal: BJU Int
    Reference: Mar;111(3):E16-7.

  • 527. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?

    Carlsson SV, Peltola MT, Sjoberg D, Schröder FH, Hugosson J, Pettersson K, Scardino PT, Vickers AJ, Lilja H, Roobol MJ, 2013

    Journal: BJU Int
    Reference: Sep;112(5):602-9.

    paper

  • 526. Excess all-cause mortality in the evaluation of a screening trial to account for selective participation.

    Kranse R, van Leeuwen PJ, Hakulinen T, Hugosson J, Tammela TL, Ciatto S, Roobol MJ, Zappa M, Aus G, Bangma CH, Moss SM, Auvinen A, Schröder FH, 2013

    Journal: J Med Screen.
    Reference: 20(1):39-45.

  • 525. Impacts of a population based prostate cancer screening programme on excess all-mortality rates in men with prostate cancer: a randomized controlled trial.

    van Leeuwen PJ, Kranse R, Hakulinen T, Hugosson J, Tammela TL, Ciatto S, Roobol MJ, Zappa M, de Koning HJ, Bangma CH, Moss SM, Auvinen A, Schröder FH, 2013

    Journal: J Med Screen
    Reference: Mar;20(1):33-8.

  • 524. Risk stratification in prostate cancer screening.

    Roobol MJ, Carlsson SV, 2013

    Journal: Nat Rev Urol
    Reference: Jan;10(1):38-48.

    paper

  • 523. Reply from Authors re: Jonathan Bergman, Mark S. Litwin. The Henderson-Hasselbalch Equation for Urologists. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.12.021: Health-related Quality-of-life Scores from the Finnish Trial of Screening for Prostate Cancer Offer One Useful Contribution.

    Booth N, Rissanen P, Tammela TL, Määttänen L, Taari K, Auvinen A, 2014

    Journal: Eur Urol
    Reference: Jan;65(1):50-1.

    paper

  • 522. Tribute to Stefano Ciatto.

    Roobol MJ; also on behalf of all members of the ERSPC, 2013

    Journal: Eur Urol
    Reference: Jan;63(1):e12-3.

    paper

  • 521. Landmarks in prostate cancer screening.

    Schröder FH, 2012

    Journal: BJU Int
    Reference: Oct;110 Suppl 1:3-7.

    paper

  • 520. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.

    Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ, 2012

    Journal: BJU Int
    Reference: Dec;110(11):1654-60.

    paper

  • 519. Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.

    Zhu X, van Leeuwen PJ, Holmberg E, Bul M, Carlsson S, Schröder FH, Roobol MJ, Hugosson J, 2012

    Journal: J Med Screen
    Reference: 19(3):133-40.

    paper

  • 518. Health-Related Quality of Life in the Finnish Trial of Screening for Prostate Cancer.

    Booth N, Rissanen P, Tammela TL, Määttänen L, Taari K, Auvinen A, 2014

    Journal: Eur Urol
    Reference: Jan;65(1):39-47.

    paper

  • 517. Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study.

    Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ, 2013

    Journal: Eur Urol
    Reference: Apr;63(4):597-603.

    paper

  • 516. A tribute to Stefano Ciatto (2 June 1949-4 May 2012).

    de Koning H, 2012

    Journal: J Med Screen
    Reference: 19(3):161-2.

  • 515. Reply from Authors re: Peter C. Albertsen. How Best To Use Our Tools? Eur Urol 2012;62:201–2

    Bul M, Roobol MJ, 2012

    Journal: Eur Urol
    Reference: Aug;62(2):203.

    paper

  • 514. Reply from Authors re: Alexandre R. Zlotta, Robert K. Nam. To Biopsy or Not to Biopsy—Thou Shall Think Twice. Eur Urol 2012;61:1115–7: Considerations for Prostate Biopsy Decisions

    Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ, 2012

    Journal: Eur Urol
    Reference: June;61(6):1117-1118.

    paper

  • 513. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.

    Loeb S, Zhu X, Schroder FH, Roobol MJ, 2012

    Journal: BJU Int.
    Reference: Dec;110(11):1678-83.

    paper

  • 512. Reply from Authors re: Noel W. Clarke. Coming Up for Air: Follow-up and Risk Stratification After Negative Prostate Cancer Screening. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.08.007: Current and Future Risk Prediction Tools: Vital for the Early Detection of Prostate Cancer.

    Zhu X, Roobol MJ, Steyerberg EW, 2012

    Journal: Eur Urol
    Reference: 63(2013)634–636

    paper

  • 511. Active surveillance for low-risk prostate cancer.

    Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A et al, 2013

    Journal: Crit Rev Oncol Hematol
    Reference: Mar;85(3):295-302

    paper

  • 510. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

    Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ, 2012

    Journal: BJU Int
    Reference: Dec;110(11):1672-7.

    paper

  • 509. Outcome Following Active Surveillance of Men with Screen-detected Prostate Cancer. Results from the Göteborg Randomised Population-based Prostate Cancer Screening Trial.

    Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J, 2013

    Journal: Eur Urol
    Reference: Jan;63(1):101-7.

    paper

  • 508. Quality-of-life effects of prostate-specific antigen screening.

    Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ., 2012

    Journal: N Engl J Med
    Reference: Aug 16;367(7):595-605.

    paper

  • 507. Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening.

    Wu GH, Auvinen A, Määttänen L, Tammela TL, Stenman UH, Hakama M, Yen AM, Chen HH, 2012

    Journal: Int J Cancer
    Reference: Sep 15;131(6):1367-75.

    paper

  • 506. Reply from Authors re: Allison S. Glass, Matthew R. Cooperberg, Peter R. Carroll. Early Detection of Prostate Cancer: More Information, More Clarity. Eur Urol 2012;62:753-55 Early Detection of Prostate Cancer: Hope for the Future.

    Schröder FH, Roobol MJ; on behalf of all co-authors, 2012

    Journal: Eur Urol
    Reference: Nov;62(5):755-756

    paper

  • 505. Reply to Alain Braillon and Gérard Dubois’ Letter to the Editor re: Fritz H. Schröder, Jonas Hugosson, Sigrid Carlsson, et al. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012;62:745-52.

    Schröder FH, Roobol MJ; on behalf of all co-authors, 2012

    Journal: Eur Urol
    Reference: Nov;62(5):e90-e91

    paper

  • 504. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.

    Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW, 2012

    Journal: Eur Urol
    Reference: Apr;63(4):627-33.

    paper

  • 503. To be screened or not to be screened? Modeling the consequences of PSA screening for the individual.

    Wever EM, Hugosson J, Heijnsdijk EA, Bangma CH, Draisma G, de Koning HJ, 2012

    Journal: Br J Cancer
    Reference: Aug 21;107(5):778-84.

    paper

  • 502. Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group.

    Ankerst DP, Boeck A, Freedland SJ, Stephen Jones J, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ et al, 2014

    Journal: World J Urol
    Reference: Feb;32(1):185-91.

    paper

  • 501. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.

    Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A, 2012

    Journal: BJU Int
    Reference: Mar;109 Suppl 2:1-7.

    paper

  • 500. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.

    Wu GH, Auvinen A, Yen AM, Hakama M, Tammela TL, Stenman UH, Kujala P, Ruutu M, Chen HH., 2012

    Journal: Eur Urol
    Reference: May;61(5):1011-8.

    paper

  • 499. Psychological aspects of active surveillance.

    van den Bergh RC, Korfage IJ, Bangma CH, 2012

    Journal: Curr Opin Urol
    Reference: May;22(3):237-42.

    paper

  • 498. The Prostate cancer Research International: Active Surveillance study.

    Bangma CH, Bul M, Roobol M, 2012

    Journal: Curr Opin Urol
    Reference: May;22(3):216-21.

    paper

  • 497. Compliance with biopsy recommendations of a prostate cancer risk calculator.

    van Vugt HA, Roobol MJ, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Steyerberg EW, Korfage I, 2012

    Journal: BJU Int
    Reference: May;109(10):1480-8.

    paper

  • 496. Prostate-specific antigen screening can be beneficial to younger and at-risk men.

    Roobol MJ, Bangma CH, Loeb S, 2012

    Journal: CMAJ
    Reference: Jan 8;185(1):47-51.

    paper

  • 495. Can the prostate risk calculator based on Western population be applied to Asian population?

    Yoon DK, Park JY, Yoon S, Park MS, Moon du G, Lee JG, Schröder FH, 2012

    Journal: Prostate
    Reference: May 15;72(7):721-9.

    paper

  • 494. Selective detection of aggressive prostate cancer.

    Schröder FH, Roobol MJ, 2012

    Journal: Cancer
    Reference: May 15;118(10):2568-70.

    paper

  • 493. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

    Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH, 2012

    Journal: Eur Urol
    Reference: Mar;61(3):577-83.

    paper

  • 492. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.

    van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Roobol MJ, 2012

    Journal: Eur J Cancer
    Reference: Aug;48(12):1809-15.

    paper

  • 491. Prostate-cancer mortality at 11 years of follow-up.

    Schröder FH, Hugosson J, Roobol MJ, et al. for the ERSPC Investigators., 2012

    Journal: N Engl J Med
    Reference: Mar 15;366(11):981-90.

    paper

  • 490. Prostate cancer: modeling the outcomes of prostate cancer screening.

    Loeb S, Carlsson S, Braithwaite RS, 2012

    Journal: Nat Rev Urol
    Reference: Mar 13;9(4):183-5.

    paper

  • 489. The impact of PLCO control arm contamination on perceived PSA screening efficacy.

    Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R, 2012

    Journal: Cancer Causes Control
    Reference: June;23(6):827-35.

    paper

  • 488. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized study of Screening for Prostate Cancer (ERSPC).

    Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ, 2012

    Journal: Eur Urol
    Reference: Nov;62(5):745-52.

    paper

  • 487. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

    Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J, 2012

    Journal: J Clin Oncol
    Reference: Jul 20;30(21):2581-4.

    paper

  • 486. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial.

    Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ, 2012

    Journal: Eur Urol
    Reference: Jun;61(6):1110-4.

    paper

  • 485. Prostate cancer epidemic in sight?

    Schröder FH, Roobol MJ, 2012

    Journal: Eur Urol
    Reference: Jun;61(6):1093-5.

    paper

  • 484. Reply to Ferhat Ates, Ilker Akyol and Hasan Soydan’s Letter to the Editor re: Meelan Bul, Xiaoye Zhu, Antti Rannikko, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.

    Bul M, Zhu X, Roobol MJ, 2012

    Journal: Eur Urol
    Reference: Jul;62(1):e10-1.

    paper

  • 483. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.

    Seiler D, Randazzo M, Klotz L, Grobholz R, Baumgartner M, Isbarn H, Recker F, Kwiatkowski M, 2012

    Journal: BJU Int
    Reference: Jul;110(2):195-200.

    paper

  • 482. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

    van Leeuwen PJ, Otto SJ, Kranse R, Roobol MJ, Bul M, Zhu X, de Koning H, Schröder FH, 2012

    Journal: BJU Int
    Reference: Jul;110(2):188-94.

    paper

  • 481. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.

    van Vugt HA, Roobol MJ, van der Poel HG, van Muilekom EH, Busstra M, Kil P, Oomens EH, Leliveld A, Bangma CH, Korfage I, Steyerberg EW, 2012

    Journal: BJu Int
    Reference: Jul;110(2):180-7.

    paper

  • 480. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy.

    Wolters T, Montironi R, Mazzucchelli R, Scarpelli M, Roobol MJ, van den Bergh RC, van Leeuwen PJ, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH, 2012

    Journal: Prostate
    Reference: Jan;72(1):108-15.

    paper

  • 479. Towards an optimal interval for prostate cancer screening.

    van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J, 2012

    Journal: Eur Urol
    Reference: Jan;61(1):171-6.

    paper

← PreviousNext →